Search results for "APR"
showing 10 items of 2648 documents
Perceptual blending in odor mixtures depends on the nature of odorants and human olfactory expertise.
2012
International audience; Our olfactory system is confronted with complex mixtures of odorants, often recognized as single entities due to odor blending (e.g., coffee). In contrast, we are also able to discriminate odors from complex mixtures (e.g., off-odors). Therefore, the olfactory system is able to engage either configural or elemental processes when confronted with mixtures. However, the rules that govern the involvement of these processes during odor perception remain poorly understood. In our first experiment, we examined whether simple odorant mixtures (binary/ternary) could elicit configural perception. Twenty untrained subjects were asked to evaluate the odor typicality of mixtures…
MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.
2021
558 Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-stage hormone receptor positive (HR+), epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Discordances in risk allocation between these platforms affect up to 30% of patients. This study aims to develop the MamaPred test to improve the diagnostic performance of recurrence risk in HR+/HER2- early-stage BC. Methods: A total of 606 HR+/HER2- early-stage BC previously tested with OT [n = 287; Low Risk (LR) = 165, Intermediate Risk (IR) = 103 and High Risk (HR) = 19] and MP (n = 3…
How to optimize HCV therapy in genotype 1 patients: predictors of response.
2013
The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin (PEG-IFN/RBV) has resulted in a significant improvement in the sustained virological response (SVR) rate and potentially in life years gained compared to dual therapy (DT), when treating naive or treatment-experienced patients with genotype 1 (G1) chronic hepatitis C (CHC). This benefit is partly offset by the increased complexity of treatment, and the increased costs and risks of therapy, making it necessary to optimize the indications for TT. Naive patients with mild fibrosis and the IL28B CC polymorphism and/or with a rapid vi…
Genomic profile of breast cancer: costeffectiveness analysis from the Spanish National Healthcare System perspective.
2014
Background: Costeffectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 …
In response: Genomic profile of breast cancer.
2015
Response to: Plun-Favreau J, Svedman C, Valentine W, Rouzier R. Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):393–94We would like to express our gratitude for th...
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association…
2013
AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-m…
Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?
2012
The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin resulted in a significant gain in terms of sustained virological response (SVR) when treating naive or previous treated patients with genotype 1 (G1) chronic hepatitis C (CHC). This gain is partly balanced by the increased complexity of treatment and by the raised costs and risks of therapy, making necessary to optimize the indication to TT. Specifically, the identification of patient needing to TT over DT, the choice of the more correct therapeutic approach according to baseline and on treatment SVR predictors, and the timing of…
Promocijas darbs
2009
Anotācija Pirmsoperācijas jeb neoadjuvantā ķīmijterapija ir ļoti cerīga vēža medikamentozās terapijas attīstības stratēģija nākotnē. Tā rada iespēju veikt krūti saglabājošu operāciju slimniecēm ar lieliem primāriem audzējiem. Slimniecēm, kurām sasniegta audzēja pilna morfoloģiska remisija pēc neoadjuvantās ķīmijterapijas operācijas materiālā, ir konstatēta garāka dzīvildze. Šī darba mērķis bija novērtēt pirmsoperācijas ķīmijterapijas, molekulāro marķieru – šūnu proliferācijas indeksa Ki-67, cilvēka epidermālā augšanas faktora receptora cerbB-2 un steroīdo hormonu receptoru lomu ārstēšanas izvēlē un bezrecidīva dzīvildzi, piecu un desmit gadu dzīvildzi slimniecēm ar lokāli izplatītu krūts vē…
Saudzējoša pēcoperācijas staru terapija agrīno stadiju krūts vēža slimnieču ārstēšanā
2009
Anotācija Agrīno stadiju krūts vēža pacientēm pēc krūti saudzējošās ārstēšanas ir prognozējama liela dzīvildze, kuras laikā var manifistēties staru terapijas komplikācijas. Darba mērķis bija noteikt saudzējošās ar elpošanu sinhronizētās pēcoperācijas staru terapijas ietekmi uz vēlīno plaušu un sirds jonizējošā starojuma izraisīto komplikāciju attīstību. Standarta un saudzējošās staru terapijas metodes tika salīdzinātas pēc terapeitiskās efektivitātes, jonizējošā starojuma dozas sadalījuma riska orgānos, komplikāciju attīstības riskiem un jonizējošā starojuma dozas piegādes precizitātes. Darba rezultātā tika pierādīts, ka saudzējošā pēcoperācijas staru terapija samazina sirds un plaušu kompl…
KUŅĢA VĒŽA ĶIRURĢISKĀS ĀRSTĒŠANAS REZULTĀTU UN KVALITĀTES RĀDĪTĀJU ANALĪZE
2012
ANOTĀCIJA. Pētījumā tika analizēti kuņģa vēža pacientu dzīvildzi ietekmējoši riska faktori: komplikācijas, paaugstināts ķermeņa masas indekss, splenektomijas, asins pārliešanas un operācijas laikā izdalīto limfmezglu skaita atvasināts parametrs – N attiecība (metastātisko un izmeklēto limfmezglu attiecība), SIA Rīgas Austrumu klīniskās universitātes slimnīcas stacionāra Latvijas Onkoloģijas centrā radikāli operētiem kuņģa vēža pacientiem. Rezultāti: Nav nozīmīgas dzīvildzes atšķirības starp pN1 un pN2 pacientu grupām pēc TNM klasifikācijas. Izmantojot N attiecību (1–25% vs. 30 10,5% (p=0,195), sakarība starp ĶMI un komplikācijām nebija statistiski ticama (p=0,152). Kaplan-Meier līknes parād…